NCT06304233View on ClinicalTrials.gov

The Protein Disrupted in Schizophrenia 1 (DISC1) as a Novel Biomarker for Cardiac Disease

Active, not recruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2038

Conditions
Heart DiseasesHeart; Functional DisturbanceSchizophrenia
Interventions
DIAGNOSTIC_TEST

Echocardiography

ultrasound assessment of heart structure, volume and function

DIAGNOSTIC_TEST

Cardiac Magnetic Resonance Imaging

MRI assessment of heart structure, volume, function and tissue characteristics

DIAGNOSTIC_TEST

Electrocardiography

Assessment of cardiac rhythm and electrical activity

OTHER

Blood sampling

To measure DISC1 mRNA expression and other potential biomarkers

Trial Locations (2)

Unknown

Norwegian University of Science and Technology, Trondheim

St Olavs Hospital, Trondheim University Hospital, Trondheim

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

lead

Norwegian University of Science and Technology

OTHER

NCT06304233 - The Protein Disrupted in Schizophrenia 1 (DISC1) as a Novel Biomarker for Cardiac Disease | Biotech Hunter | Biotech Hunter